基本资料
投资组合
财务数据
基金公告
港股通创新药ETF华宝(520880) |
净值:
0.4465
|
日增长率:
-1.57%
|
累计净值:0.8930 | 2026-09-28 |
|
|
||||
| 股票代码 | 股票简称 | 持股数量(股) | 持股市值(元) | 占基金净值比(%) |
| 01801 | 信达生物 | 3,514,500.00 | 242,980,510.41 | 10.64 |
| 06160 | 百济神州 | 1,641,700.00 | 242,973,110.36 | 10.64 |
| 01093 | 石药集团 | 34,320,000.00 | 207,766,192.92 | 9.10 |
| 09926 | 康方生物 | 2,631,000.00 | 201,207,902.15 | 8.81 |
| 01177 | 中国生物制药 | 43,906,000.00 | 168,173,393.28 | 7.36 |
| 03692 | 翰森制药 | 6,442,000.00 | 165,729,797.34 | 7.26 |
| 01530 | 三生制药 | 8,639,500.00 | 126,739,819.18 | 5.55 |
| 06990 | 科伦博泰生物 | 277,100.00 | 104,982,524.42 | 4.60 |
| 09688 | 再鼎医药 | 4,826,000.00 | 60,610,858.46 | 2.65 |
| 02162 | 康诺亚-B | 953,000.00 | 58,561,766.61 | 2.56 |
| 报告期 | 股票占净比(%) | 债券占净比(%) | 现金占净比(%) | 净资产(元) |
| 2026-06-30 | 99.58 | - | 0.83 | 2,284,319,295.67 |
| 2026-03-31 | 99.62 | - | 2.21 | 2,303,891,783.67 |
| 2025-12-31 | 99.56 | - | 1.02 | 2,099,952,291.45 |
| 2025-09-30 | 99.38 | - | 0.81 | 1,805,799,836.44 |
| 2025-06-30 | 18.08 | - | 99.98 | 434,945,030.84 |